| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Blume-Jensen Peter | President and CEO, Director | C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN | /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen | 16 Jan 2026 | 0001950499 |
| Masson Kristina | EVP - Business Operations, Director | C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN | /s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson | 16 Jan 2026 | 0001950501 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ACRV | Common Stock | Purchase | $82,124 | +49,000 | +2.4% | $1.68 | 2,095,771 | 14 Jan 2026 | Direct | F1, F2 |
| holding | ACRV | Common Stock | 314,706 | 14 Jan 2026 | See Footnote | F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.66 to $1.68, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4. |
| F2 | These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. |
| F3 | These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |